OCTAGON CAPITAL ADVISORS LP other names

{{ Info.Overview }}
Revenue: {{ Info.Revenue | formatUSD }} Headquarters: {{ Info.Headquarters }}
{{ Info.Homepage }}

Adviser Profile

As of Date:

03/21/2024

Adviser Type:

- Large advisory firm

Number of Employees:

9

of those in investment advisory functions:

7 16.67%

Registration:

SEC, Approved, 4/27/2020

Other registrations (1)
Former registrations

OCTAGON CAPITAL ADVISORS LP

AUM:

951,771,000 -11.42%

of that, discretionary:

951,771,000 -11.42%

GAV:

951,770,000 -11.42%

Avg Account Size:

158,628,500 -11.42%

SMA’s:

NO

Private Funds:

3

Contact Info

212 xxxxxxx

Websites :
Client Types:

+

Advisory Activities:

+

Compensation Arrangments:

+

Reported AUM

Discretionary
Non-discretionary
1B 957M 797M 638M 478M 319M 159M
2020 2021 2022 2023

Recent News

Octagon Capital Advisors LP Buys Apellis Pharmaceuticals Inc, Celldex Therapeutics Inc, Cytek ...
11/16/2021

Related Stocks: APLS, CLDX, BBIO, RCUS, IPSC, CTKB, OMGA, TENX, ZLAB, XLRN, TSHA, KYMR, MRUS, RVMD,

gurufocus.com

NiKang's new CFO appointment pays off with $200M fund raise from her previous employer
05/26/2021

In conjunction with the financing, NiKang is boosting its board with former Viela Bio Chairman Bing Yao, Ph.D., and Octagon Capital Chief Investment ...

fiercebiotech.com

Oceanpine Capital leads $73m funding in US biopharma firm Immune-Onc
04/01/2021

Tao Capital and Yinglian Healthcare Fund. The Leukemia & Lymphoma Society’s Therapy Acceleration Program, Octagon Capital and Sphera Healthcare also participated in the financing. Proceeds from the latest funding round will support the development of ...

dealstreetasia.com

Immune-Onc Therapeutics Announces $73 Million in Series B1 and B2 Financing to Advance its Portfolio of Novel Immunotherapies in Blood Cancers and Solid Tumors
03/30/2021

The round was led by Oceanpine Capital with participation from additional new investors including Octagon Capital and Sphera Healthcare, and existing investors, including Northern Light Venture ...

businesswire.com

China Digest: Bioheng snags $80m; 5Y Capital backs Chocday
03/26/2021

Immunotherapy-focused Nanjing Bioheng Biotech Company Limited has completed its 520 million yuan ($80 million) Series B round of financing co-led by Hillhouse Capital’s venture unit GL Ventures, Octagon Capital and existing investor Decheng Capital.

dealstreetasia.com

Bioheng Biotech Raised $80 million in Series B Financing to Advance Allogeneic Immuno-Cell Therapies
03/24/2021

Octagon Capital manages capital on behalf of global institutions such as university endowments, non-profit foundations, family offices, pension funds and established asset managers. About BlueRun ...

asiaone.com


Private Funds Structure

Fund Type Count GAV
Hedge Fund 1 $834,239,000
Private Equity Fund 2 $117,531,000

Similar advisers

Adviser Hedge Fund Liquidity Fund Private Equity Fund Real Estate Fund Securitized Asset Fund Venture Capital Fund Other Fund Total Private Fund GAV AUM # funds
HONEYCOMB ASSET MANAGEMENT LP 728.8m - 19.4m - - - - 748.3m 748.3m 3
CORRE PARTNERS MANAGEMENT, LLC 823.2m - 289.4m - - - - 1.1b 1.1b 3
ROSEMAWR MANAGEMENT LLC 798.6m - 634.0m - - - - 1.4b 1.4b 7
BOW STREET LLC 84.4m - 344.6m - - - - 429.0m 608.1m 6
MERCED CAPITAL, L.P. 109.3m - 441.9m 84.7m - - - 635.9m 635.9m 7
THORNTREE CAPITAL PARTNERS LP 725.5m - 26.8m - - - - 752.3m 752.3m 3
COOK PINE CAPITAL LLC 68.6m - 191.7m - - - - 260.3m 409.2m 3
HIDDEN LAKE ASSET MANAGEMENT LP 387.1m - 2.5m - - - - 389.6m 389.6m 4
TENSILE CAPITAL MANAGEMENT LP 1.9b - 49.3m - - - - 1.9b 1.9b 3
BOSTWICK CAPITAL LLC 138.7m - 121.6m - - - - 260.2m 260.2m 4

Private Funds



Employees




Brochure Summary

Overview

A. Octagon is a Delaware limited partnership formed on October 30, 2019, to operate as an investment adviser with offices in New York, New York. Octagon is principally owned by Ting Jia. References to “us,” “we,” or “our” in this Brochure refer to Octagon. We provide discretionary investment advisory services to master-feeder, mini-master feeder, and Delaware series trust structures comprised of affiliated pooled investment vehicles (each, a “Fund,” and collectively, the “Funds”). We may in the future also provide investment advisory services to Separately Managed Accounts (“SMAs,” collectively with the Funds, “Clients”). We generally seek to provide attractive risk-adjusted returns by investing in healthcare companies with long-term compounding growth potentials on behalf of Clients. Clients typically invest in securities and financial instruments of companies in the healthcare sector globally, with focuses in companies headquartered in the United States, China, the European Union, and the United Kingdom. Clients may
invest in securities on the open market, private placements, bonds, warrants, debt, convertible debt, or securities, secondary or initial public offerings (“IPOs”); and/or other assets and financial instruments. B. We manage Client investments in accordance with investment objectives, strategies, guidelines, and terms and conditions, as outlined in each Client’s applicable advisory agreement(s) or other governing document(s) (collectively, “Governing Documents”). Octagon does not, however, provide individualized investment advice or tailor its advisory services to the individual needs of any Fund’s underlying investors (“Investors”). Octagon may enter into side letters with certain Investors, which could alter or supplement the terms of such Investor’s investment. C. We do not participate in wrap-fee programs. D. As of December 31, 2022, we managed approximately $1,074,417,782 in regulatory assets under management on a discretionary basis. We do not manage any non-discretionary assets.